LIMS Add Competitive Advantage To CDMOs LIMS Add Competitive Advantage To CDMOs
Pharma Tech Outlook
Home ยป News

LIMS Add Competitive Advantage To CDMOs

Pharma Tech Outlook | Friday, September 02, 2022

Contract and development manufacturing organizations (CDMOs) are a major resource in pharmaceutical & biotech product development, not only for smaller companies lacking research and manufacturing facilities but also for large organizations needing specific expertise.

Lab information management systems (LIMS) are a key element in successful CDMOs, helping them transition to Industry 4.0 during the research and development phase, with synergies that even ease the path to manufacturing. This is particularly beneficial as the economy tightens.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

The growing need for CDMOs is part of the general trends toward outsourcing. For many companies, it is an economic imperative that helps companies use their capital and their intellectual resources as efficiently as possible. It has become integral in the development and success of many life sciences companies. To that point, Absolute Market Insights valued CDMO revenues at more than $159 billion in 2022 and projected an 8% compound annual growth rate (CAGR) through 2030.

CDMOs’ most recent surge was fueled by their role in bridging the manufacturing gap caused by the need to manufacture COVID-19 vaccines and therapeutics at previously unheard-of quantities and within short timelines. That is only part of the picture, though. Non-COVID-related research, development, and manufacturing activities also grew. For example, when the Federal Reserve Bank cut interest rates to 0% in March 2020, investment capital poured into biotech. CDMO valuations soared. Reported profits for public CDMOs ranged from 10% to 20% through mid-2021.

Economic indicators for 2022, however, are not as bright. The initial public offering (IPO) window is all but closed, interest rates are rising, and stock prices are plummeting. Biotech company valuations are slumping. Economists are discussing a recession.

To thrive in such an environment, CDMOs must operate with extreme efficiency.

That entails embracing the data-driven research and development that is part of Industry 4.0. Advanced analytics, including lab information management systems (LIMS), is a key part of that.

When applied organization-wide, digital informatics enables a comprehensive view of operations, deep insights, greater control, and on-the-spot reports that include trends, certificates of analysis, condition reports, and periodic reports. Consequently, organizations have the data needed to make real-time improvements to operations and products. For example, one lab found that by using a LIMS, overall data quality improved and the time spent entering and retrieving data was reduced. By expanding access to the data, it also found that researchers gained novel perspectives.

That is because data stored in a LIMS is never buried in inaccessible silos or updated in one database but not another. Instead, LIMS integration makes data, including inventories, experiment results, issues, and reports accessible system-wide instantly. As a result, issues can be addressed, and product development can advance with everyone working from the same source of truth. This enables fast knowledge transfer that speeds process development and contributes to a streamlined, iterative approach to therapeutic development.

Because reports can be generated from master data within the LIMS, the need for manual data input is reduced. Accuracy, therefore, improves.

This wide-scale digitization creates an audit-friendly environment that supports regulatory filings. The key is the accurate and easy report generation that emanates from a sole source of truth. Therefore, the data-gathering, report-generating aspects of the investigational new drug (IND), new drug application (NDA), biologics license application (BLA), and other filings are significantly streamlined. Applications can be filled faster and easier, and with the exacting data integrity that regulators demand.

Initially, for CDMOs, LIMS’ most notable features may be their ability to integrate instruments into the system and then automate manual processes, procedures, and tasks throughout the research and development phases. This includes equipment maintenance and personnel training records. As a result, managers know whether individual staff members are properly trained on specific procedures, instruments, and equipment and whether instruments and equipment are properly calibrated and maintained and, therefore, whether they can be used with confidence.

Most individual lab instruments are used for drug development support integration, either through internal applications, third-party software solutions, or application programming interfaces (APIs). The level of integration can be one-way (from the instrument to the LIMS) or bi-directional, to support such activities as batch setups, automated instrument calibration, instrument control, or decision-making.

LIMS do more than track experiment results, projects, or inventory, of course. They also can identify researchers on a given project, identify next steps, improve workflow, alert users to important dates in schedules or inventory levels, inform users regarding proper sample storage and instrument use and analyze any laboratory backlogs. With these capabilities, CDMOs can gain insight into their labs’ efficiency and use that knowledge to make improvements.

LIMS also can perform – or link to solutions that perform – scientific calculations, thus removing another potential error source. Other capabilities include automating testing analysis and tracking trends, thus freeing staff for more value-added activities. With such wide-ranging capabilities, managers can establish management-by-exception protocols so quality assurance professionals need only review data that falls outside specified parameters, further enhancing productivity.

These systems can further slice and dice the data by generating reports based on the instrument, project, client, or lab technician. This data can then be used to balance or prioritize workloads as new projects and activities are considered.

On the manufacturing side, manufacturing systems and learning management systems can be integrated into LIMS. This may be particularly beneficial as projects scale from the bench to the manufacturing suite, enabling a broader view of the development and manufacturing environment for a given product.

Throughout development, LIMS make it possible to leverage both immediate and predictive analysis to better transition to the next step in a drug’s design and development. By leveraging the vast quantities of data available through an integrated LIMS, predictive models can be more accurate than those developed otherwise. A variety of visualization methods helps users consider it in many ways and present it effectively to various audiences.

Because data and reports can be accessed from one dashboard, data visualization may be more comprehensive and project workflow management may improve. Depending on the LIMS chosen, even some business and accounting systems can be integrated into the system to support lifecycle management.

When it is time to transfer development to other facilities or back to the client, having a robust LIMS aids the process by ensuring that the new facilities have all the supporting documentation for the process or product, both current and historical. Having thorough, well-organized digital processes in place has become a competitive advantage for CDMOs, helping them attract clients by reducing product variability and improving quality, and by smoothing tech transfer.

For CDMOs, the digital infrastructure and manufacturing infrastructure go together. It takes both to develop and manufacture therapeutics of consistently high quality that meet the requirements of the FDA and other regulators. By providing a thorough data-based history throughout a drug’s development, LIMS systems help position life science companies for success.

More in News

Commercial pharmaceutical teams can spend weeks preparing an analysis only to find that prescribing patterns or market access conditions have changed before the recommendations reach the field. A segmentation exercise commissioned against an earlier data extract may be technically sound but poorly timed. Executives evaluating agentic data science platforms must establish whether faster answers preserve analytical consistency and remain grounded in approved enterprise data. Speed alone offers little protection against an incorrect calculation reaching a brand team. Repeated preparation of structured data consumes substantial analyst time. Patient records and physician activity may sit in different datasets, each requiring defined relationships before a commercial question can be answered. A platform should preserve those definitions between analyses rather than reconstruct them for every request. Otherwise, two teams examining the same treatment pathway may produce different results because they applied different filters. Buyers should examine how business rules are encoded and how the system establishes which records are eligible for a particular analysis. Traceable calculations matter more than fluent explanations. Generative AI introduces a specific division of responsibility. Natural language interfaces make complex analysis accessible to commercial managers, but language models are not dependable numerical engines by themselves. Agentic platforms should separate interpretation of a request from execution of statistical calculations, using controlled methods for the latter. The system must also handle longer workflows that require successive analytical steps rather than treating every request as an isolated query. Results should be reproducible when the same data and assumptions are supplied, with sufficient detail for data scientists to review the method. “Orcana's semantic layer maintains enterprise data definitions and business rules across analyses, keeping the same assumptions available to different teams.” Pharmaceutical data access comes with restrictions that ordinary business intelligence implementations may not encounter. Patient-level records require appropriate privacy controls, while commercial functions may have different permissions to view measures or underlying datasets. An automated agent working across several analytical steps must retain those restrictions throughout the process. Executives should establish whether permissions and approved channel definitions are enforced by the architecture itself or depend on users phrasing prompts correctly. The latter creates unnecessary room for inconsistent handling of sensitive information. Commercial usefulness depends on the time between finding a pattern and changing an action. Campaign measurement may identify underperforming promotional channels, while a market access analysis can reveal barriers affecting a particular patient population. Neither finding improves execution automatically. Buyers should examine how outputs reach existing field systems and whether recommended changes remain subject to appropriate review. Reusable workflows should also accommodate updated data, permitting teams to revisit earlier decisions without commissioning a complete analysis each time. Orcana provides a pharma-focused agentic data science platform that combines generative AI for interpreting requests with a deterministic Python engine for calculations. Orcana's semantic layer maintains enterprise data definitions and business rules across analyses, keeping the same assumptions available to different teams. Its specialized agents support segmentation, marketing mix assessment and campaign measurement, alongside treatment-pathway analysis. Orcana uses governed workflows and access restrictions to control what agents can analyze and disclose. Its analytics bench addresses recurring questions, while deeper agents handle extended analytical work that would otherwise require separate projects. Pharmaceutical commercial analytics teams managing repeated cross-brand studies, particularly those needing reproducible calculations within established data permissions, are the intended users of this approach. ...Read more
AI in pharmaceutical compliance streamlines documentation, mitigates risks, enhances accuracy, automates regulatory processes, and ensures timely, proactive compliance. Pharmaceutical compliance is undergoing a revolution because of AI's application, which is increasing overall efficiency, improving accuracy, and simplifying procedures. Pharmaceutical businesses may reduce risks, negotiate the complicated regulatory environment, and guarantee the safety and effectiveness of their products by using AI to automate crucial compliance processes. Regulatory compliance requires vast documentation, including clinical trial data, manufacturing records, labeling information, and adverse event reports. AI-driven systems, such as NLP and machine learning, can automate extracting, organizing, and classifying critical information from these documents. This accelerates the process and reduces the risk of human error, which is crucial for ensuring compliance. For example, AI-powered software can scan large volumes of unstructured text in clinical trial reports or regulatory submissions to extract relevant information. These systems can then flag inconsistencies, missing data, or non-compliance with specific regulatory requirements, which ensures more accurate and efficient compliance monitoring. AI can process and analyze large datasets, enabling pharmaceutical companies to identify potential risks before they become significant. For instance, predictive analytics can analyze past regulatory inspections, adverse events, or product failures to forecast potential compliance issues. This proactive approach allows companies to address problems early in drug development or post-market monitoring. AI tools also assist pharmacovigilance by analyzing real-time data from diverse sources, such as social media, electronic health records, and patient-reported outcomes. These tools can identify emerging safety concerns faster than traditional manual methods, enabling timely intervention and compliance with post-market surveillance requirements. AI can significantly speed up the preparation of regulatory filings, which are often time-consuming and require meticulous attention to detail. By automating the preparation and submission of regulatory documents, AI tools help reduce human error and ensure filings comply with the latest regulations. AI can also help companies navigate the complexity of varying regulatory standards across countries and regions. For example, an AI-driven system can automatically adapt a regulatory submission to meet the specific requirements of the FDA, EMA, or other agencies, minimizing delays and improving the chances of approval. Compliance is a constant process that requires continuous monitoring and adaptation to evolving regulations. AI can support continuous compliance by automating routine compliance checks and monitoring regulatory changes. With AI, pharma companies can stay up to date with changing guidelines, automatically integrating new regulations into their compliance protocols. For instance, AI-powered tools can scan updates to global regulations and alert companies to any changes that could impact their operations. This ensures compliance teams are always aware of new requirements and can quickly adapt their processes accordingly. ...Read more
Plenty of supplement formulations look perfect on paper. The ingredients meet spec, and then the capsules hit the filling line. Shells that vary in size cause feeding problems. The wrong shell material can hurt stability or stop the finished product from meeting labeling requirements. The formula is ready, yet production stalls. Picking a two-piece hard shell capsule maker comes down to what the shell is made of, how it runs on the line and whether supply holds up. Shell material is about more than a vegetarian label. Gelatin is still a staple in pharmaceutical manufacturing because of its cost and well-understood processing. HPMC (hydroxypropyl methylcellulose) and pullulan, the plant-based options, each bring something different. Pullulan, for one, is a good oxygen barrier, which matters for ingredients that oxidize easily. So the real question for buyers is how sensitive the formula is and where it will be stored. Plant-based shells are not all the same. Organic certification is a separate hurdle. A product full of certified organic ingredients can still run into labeling restrictions if the shell does not qualify. Anyone building an organic line needs proof that the whole capsule is certified, down to its source materials. It also pays to ask how the supplier controls raw materials and keeps them consistent from batch to batch. When material properties drift, capsule formation and filling can suffer, and more so as volumes rise. “Bright Pharma Caps makes two-piece hard shell capsules, including certified organic pullulan shells for supplement makers that need them.” Then there is size. High-speed encapsulation machines need consistent capsule geometry to separate and fill shells without constant stops. Batch-to-batch variation means more adjustments and more rejects. Ask suppliers how they hold tolerances and whether their equipment keeps variation low. Better yet, run trials on your own filling machines before signing a large supply deal. Some specialized formulas also need delayed-release shells that survive stomach acid for a set time. Those claims should be backed by dissolution testing. The risks do not stop at the factory gate either. Poor temperature or humidity control in a warehouse or truck can change how shells perform by the time they reach production. Check how the supplier ships capsules and what it does with affected lots. Steady supply matters most when you launch a new product or ramp up output. Regional stock can shorten replenishment times, though capacity plans should follow projected demand, not just current orders. Bright Pharma Caps makes two-piece hard shell capsules, including certified organic pullulan shells for supplement makers that need them. It produces its own organic pullulan in dedicated facilities, so a critical input stays under its control. Its machines run on electromagnetic rather than hydraulic systems, which cuts vibration and delivers tighter dimensional tolerances for high-speed filling. The range also covers HPMC delayed-release capsules, and organic liquid-fill options are in development. Several warehouses handle distribution, and technical support is on hand for capsule-related manufacturing questions. For nutraceutical producers that care most about organic certification, consistent filling and reliable resupply, it is a strong fit. ...Read more
In recent years, researchers at the intersection of computer science and biology have found it increasingly straightforward to obtain funding for commercializing their innovations. The approach is both simple and powerful: leveraging large datasets and machine learning to tackle persistent challenges in drug discovery, development, and testing. Nevertheless, many of these initial drug initiatives have encountered difficulties. It is crucial for both the field and patients to comprehend the reasons behind these setbacks and to address these developmental challenges. Patient Data is Fundamental Transferring cutting-edge knowledge from academic laboratories to address specific technical challenges using clearly defined datasets has been established as a successful strategy in technology and biotechnology. However, integrating Artificial Intelligence (AI) into medicine—frequently referred to as 'techbio'—tends to comprehensively emphasize biological aspects over technological ones. The data essential for success in this domain is typically more diverse, sourced from various locations, and, importantly, derived from actual patients within the intricate landscape of different healthcare environments. Staying Close to Academia: In the development of medicine, human intelligence must take precedence over artificial intelligence both initially and subsequently. This intelligence is predominantly found within universities and research hospitals. Therefore, a vital component in enhancing the efficacy of AI in the creation of superior medical solutions is the establishment of robust and enduring collaborations with these academic and research institutions. This process is not merely unidirectional; it constitutes a network of continuous engagement among academia, pharmaceutical companies, and biotechnology firms. Innovative collaboration methods, such as privacy-preserving federated learning, enable training machine learning models on extensive multimodal datasets without the need to transfer them. This approach can significantly advance fundamental research, diagnostics, and drug discovery, yielding numerous patient advantages while safeguarding privacy and optimizing the utilization of diverse data sources. Multi-Dimensional Problems Require Multimodal Data: At this point in the evolution of artificial intelligence within medicine, it is evident that AI provides us with a novel perspective on human biology. For instance, a single digital pathology slide encompasses a volume of data comparable to that of a feature-length film, and only through machine learning can we fully leverage this information. However, to comprehend diseases and influence their trajectories, it is crucial to acknowledge the intricate nature of biology across all levels—from molecules to cells, tissues, the disease microenvironment, and the organism in its entirety. To achieve this, advancing AI capabilities beyond unimodal tasks is imperative. We must integrate medical imaging with cutting-edge molecular profiling technologies that capture the activity and localization of biomolecules, known as spatial omics, thereby connecting the microscopic with the macroscopic. By combining AI with such comprehensive datasets, we can gain insights into diseases, from their predisposition to their progression and treatment. ...Read more

Weekly Brief